Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ascendis Pharma ASASND +2.33%37 Equity-to-Asset is 0.24 as of Mar. 2026, which is 71% below its 10-year median of 0.83. GuruFocus rates ASND with a GF Score™ of 37/100. The stock has 1 warning sign investors should review. Among 1,416 Biotechnology companies, Ascendis Pharma AS ranks worse than 81% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Ascendis Pharma AS's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $564 Mil. Ascendis Pharma AS's Total Assets for the quarter that ended in Mar. 2026 was $2,316 Mil.
Therefore, Ascendis Pharma AS's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.24.
The historical rank and industry rank for Ascendis Pharma AS's Equity-to-Asset or its related term are showing as below:
ASND'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.42 Med: 0.83 Max: 0.95
Current: 0.24
During the past 13 years, the highest Equity to Asset Ratio of Ascendis Pharma AS was 0.95. The lowest was -0.42. And the median was 0.83.
ASND's Equity-to-Asset is ranked worse than 81% of 1416
companies
in the Biotechnology industry
Industry Median: 0.68
vs ASND: 0.24
Ascendis Pharma AS (NAS:ASND) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Ascendis Pharma AS Equity-to-Asset Related Terms
Ascendis Pharma AS Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Ascendis Pharma AS's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASND vs BBIO, JAZZ, EXEL: Equity-to-Asset Comparison
For the Biotechnology subindustry, Ascendis Pharma AS's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascendis Pharma AS Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Ascendis Pharma AS's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Ascendis Pharma AS's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascendis Pharma AS (ASND) has a Equity-to-Asset of 0.24 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Ascendis Pharma AS and its competitors. This is 71% below median its historical median of 0.83. According to the industry distribution chart, Ascendis Pharma AS ranks #1147 out of 1416 companies in the Biotechnology industry, placing it in the top 81%.
Is Ascendis Pharma AS's Equity-to-Asset too high?
Ascendis Pharma AS's current Equity-to-Asset of 0.24 is 71% below median its 10-year median of 0.83. The Biotechnology industry median Equity-to-Asset is 0.68. Ascendis Pharma AS's value of 0.24 is 64.7% below this industry median. Based on the distribution chart, Ascendis Pharma AS ranks #1147 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ascendis Pharma AS has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's Equity-to-Asset compare to BBIO and JAZZ?
According to the Biotechnology industry distribution chart, Ascendis Pharma AS ranks #1147 out of 1416 companies for Equity-to-Asset. This places Ascendis Pharma AS in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Ascendis Pharma AS's value of 0.24 is 64.7% below this benchmark. While the company's 10-year median is 0.83 vs. the industry median of 0.68, Ascendis Pharma AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascendis Pharma AS's current Equity-to-Asset of 0.24 is 64.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Ascendis Pharma AS and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascendis Pharma AS's current Equity-to-Asset is 0.24, which is 71% below median its own 10-year median of 0.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (ASND) has a current Equity-to-Asset of 0.24. The current Equity-to-Asset is 0.24, which is 71% below median its 10-year median of 0.83 and 64.7% below the Biotechnology industry median of 0.68. Ascendis Pharma AS's overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Ascendis Pharma AS (ASND), the current Equity-to-Asset is 0.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
37GF Score
Get the complete analysis for ASND
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASND has been successfully added to your 
